GlaxoSmithKline's Arnuity Ellipta, or fluticasone furoate, was approved by the FDA as a maintenance treatment for children with asthma who are at least 5 years old. The drug was previously approved for use among patients ages 12 and older.
FDA expands use of GSK's Arnuity Ellipta for pediatric asthma
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.